ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.726,76
-0,21%
S&P 500
5.316,14
0,15%
Dow Jones
39.848,92
0,11%
Euro vs US Dollar
1,08535
-0,06%
Bitcoin
69.774,70
-2,34%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Nabriva Therapeutics PLC (NBRV)

  7. Nabriva Therapeutics PLC (NBRV) News

NBRV

Nabriva Therapeutics (NBRV)

Nabriva Therapeutics PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NBRV
DatumZeitQuelleÜberschriftSymbolFirma
25/10/202319h43Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:NBRVNabriva Therapeutics PLC
25/10/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NBRVNabriva Therapeutics PLC
20/10/202303h01Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NBRVNabriva Therapeutics PLC
20/10/202302h22Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:NBRVNabriva Therapeutics PLC
31/07/202314h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBRVNabriva Therapeutics PLC
24/07/202315h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBRVNabriva Therapeutics PLC
10/07/202323h49Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NBRVNabriva Therapeutics PLC
10/07/202322h01GlobeNewswire Inc.Arbutus Appoints Two New ExecutivesNASDAQ:NBRVNabriva Therapeutics PLC
07/07/202322h34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBRVNabriva Therapeutics PLC
01/06/202322h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NBRVNabriva Therapeutics PLC
22/05/202322h02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NBRVNabriva Therapeutics PLC
15/05/202323h25Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:NBRVNabriva Therapeutics PLC
31/03/202322h30Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:NBRVNabriva Therapeutics PLC
20/01/202312h05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NBRVNabriva Therapeutics PLC
10/01/202323h59Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
10/01/202323h57Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
06/01/202313h01GlobeNewswire Inc.Nabriva Therapeutics Provides Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
05/01/202300h10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
05/01/202300h09Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
08/12/202222h38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
02/12/202223h18Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
29/11/202212h30TipRanksAnalysts Conflicted on These Healthcare Names: Nabriva (NBRV), Vir Biotechnology (VIR) and Greenwich LifeSciences (GLSI)NASDAQ:NBRVNabriva Therapeutics PLC
28/11/202213h01GlobeNewswire Inc.Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNASDAQ:NBRVNabriva Therapeutics PLC
10/11/202222h12Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NBRVNabriva Therapeutics PLC
10/11/202222h07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NBRVNabriva Therapeutics PLC
10/11/202222h01GlobeNewswire Inc.Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
08/11/202223h27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
07/11/202213h01GlobeNewswire Inc.Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022NASDAQ:NBRVNabriva Therapeutics PLC
01/11/202222h09Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
04/10/202222h05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NBRVNabriva Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:NBRV

Kürzlich von Ihnen besucht

NYSE
MCD
McDonalds
USOTC
BNPQY
BNP Paribas (QX)
DBI
SDXP
SDAX
AMEX
XLF
Financial Select Sector
CCOM
US100
US Tech 100
TG
DBK
Deutsche Bank
NYSE
KO
Coca Cola
NYSE
DIS
Walt Disney
CCOM
US500
US 500
USOTC
ADDYY
Adidas (QX)
NASDAQ
NVDA
NVIDIA
TG
BAS
BASF
TG
432
Arbor Metals
NYSE
NKE
Nike
AMEX
XLE
Energy Select Sector SPDR
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten